MetaCap

CryoPort (CYRX) vs Omeros (OMER)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CryoPort (CYRX) has outperformed Omeros (OMER) over the past year, gaining 117.0% versus a gain of 48.9%. Over five years, OMER leads with a +77.8% price change compared with -71.4% for CYRX. Omeros is the larger company by market cap ($983.7 million vs $964.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CYRX+116.97%OMER+48.93%
+145%+63%-20%
Nov 21, 20251 yearNov 20, 2026
CYRX-73.63%OMER+67.64%
+167%+31%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CYRX versus OMER key metrics
MetricCYRXOMER
Share price$19.05$13.21
Market cap$964.87M$983.66M
1-day change-2.56%-5.71%
YTD return+98.44%-23.11%
1-year return+116.97%+48.93%
5-year return-71.38%+77.79%
P/E ratio (TTM)—15.92
Forward P/E—11.95
EPS (TTM)$-0.90$0.83
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$176.18M—
Revenue growth (YoY)+12.38%—
Net income (latest FY)$78.30M$-3.35M
Gross margin47.14%—
Operating margin-20.89%—
Net margin44.44%—
52-week high$21.78$21.24
52-week low$7.61$6.70
Distance from 52-week high-12.53%-37.81%
Analyst consensusstrong_buybuy
Avg. price target upside+17.22%+108.18%
Average volume843.80K1.36M
Shares outstanding50.65M74.46M
Employees684175
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CYRX has outperformed OMER by 68.0 percentage points over the past year.

About CryoPort

CYRX stock →

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.

Health Care · Biotechnology: Pharmaceutical Preparations · 684 employees

About Omeros

OMER stock →

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees

CYRX vs OMER FAQ

Which is bigger, CryoPort or Omeros?

Omeros (OMER) is larger, with a market capitalization of $983.66M compared with $964.87M for CryoPort (CYRX).

Which stock has performed better over the past year, CYRX or OMER?

CYRX returned +116.97% over the past 12 months, compared with +48.93% for OMER (price return, excluding dividends). Past performance does not predict future results.

Are CryoPort and Omeros in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons